Car-t cell, and preparation method therefor and use thereof

By inserting the CAR gene into a specific site on T cells using the CRISPR/Cas system, the problems of virus use and random integration in existing CAR-T cell preparation have been solved, resulting in reduced costs, reduced risks, and improved expression uniformity.

WO2026233345A1PCT designated stage Publication Date: 2026-11-12JUVENTAS UNICARE PHARM (BEIJING) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/095114
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-07
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing CAR-T cell preparation methods have drawbacks such as tumorigenicity risks due to viral use, random integration issues, high production costs, and heterogeneous CAR expression.

Method used

Gene editing was performed using the CRISPR/Cas system, and CAR genes were inserted into specific sites on T cells through non-viral site-directed integration technology, avoiding viral use, improving the uniformity of CAR expression and reducing the risk of tumorigenesis.

Benefits of technology

It reduces production costs, decreases quality control procedures, significantly reduces tumorigenicity, and improves CAR expression intensity and uniformity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2026095114_12112026_PF_FP_ABST
    Figure CN2026095114_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a CAR-T cell, and a preparation method therefor and a use thereof. The preparation method for the CAR-T cell comprises the following steps: introducing a gene editing tool into a T cell to knock out a gene at a specific site in the genome of the T cell; and introducing a donor template into the T cell to knock in a CAR gene at the specific site. By means of CRISPR-Cas9 technology, a non-viral CAR-γδT cell having a site‑specifically integrated CAR gene is developed. Moreover, the preparation method for the CAR-T cell avoids the use of a virus, can significantly reduce production costs, can lower the tumorigenic risk resulting from random insertion, can improve the uniformity of CAR expression, and can increase the CAR expression intensity of the CARγδT cell.
Need to check novelty before this filing date? Find Prior Art

Description

A CAR-T cell, its preparation method and uses Technical Field

[0001] This invention relates to the field of biomedicine, and in particular to a CAR-T cell, its preparation method, and its uses. Background Technology

[0002] In recent years, chimeric antigen receptor T-cell (CAR)-T cell therapy has developed rapidly, showing great potential in cancer treatment. However, current treatment methods still have some limitations, including complex manufacturing processes, high production costs, long preparation times, and potential tumorigenicity issues. Lentiviral transduction of the CAR gene is used in CAR-T cell production because this method has drawbacks, including an increased risk of tumor development due to the insertion of oncogenes and the high cost of virus production. Although strategies such as transposon systems and mRNA transduction have been used to generate virus-free CAR-T cells, random integration and transient CAR expression lead to low homogeneity. Recently, some studies have shown that genome editing technology can be used to generate CAR-T cells by using adeno-associated virus (AAV) vectors as templates to generate CAR genes integrated at specific sites. Furthermore, non-viral strategies have been employed to achieve precise insertion of T-cell receptor (TCR) elements, resulting in the production of TCR-T cells.

[0003] γδT cells are a subset of T cells, primarily found in tissues, accounting for 1% to 5% of circulating T cells. Their TCR is composed of γ and δ subunits. Unlike αβT cells, γδT cell activation is not affected by patient-specific MHC molecules, meaning they recognize tumor-associated antigens in an MHC-independent manner. Therefore, allogeneic γδT cells do not induce graft-versus-host disease (GVHD). In 2015, an analysis of the transcriptional profiles of tumor samples from 5872 patients with 25 types of malignant tumors revealed a correlation between γδT cells and overall survival. In 2007, a study by KT Godder et al. found that patients with higher γδT cell levels after hematopoietic stem cell transplantation had a five-year survival rate of 54.4% and an overall survival rate of 70.8%, while patients with lower γδT cell levels had a five-year survival rate of 19.1% and an overall survival rate of 19.6%. Therefore, γδT cells play an important role in disease control and overall survival. Currently, lentiviruses are used to integrate γδT cells, but CAR-expressed γδT cells show lower MFI (mean fluorescence intensity).

[0004] There is an urgent need for a method to prepare CAR-T cells that can avoid the use of viruses and solve the problem of random integration. Summary of the Invention

[0005] The purpose of this invention is to provide a CAR-T cell, its preparation method, and its uses. The method for preparing CAR-T cells in this invention can integrate the CAR gene at a specific site in the genome of T cells, avoiding the use of viruses and reducing the risk of tumorigenesis caused by random integration.

[0006] To achieve the above objectives, the present invention provides a method for preparing CAR-T cells, comprising the following steps:

[0007] Introducing gene-editing tools into T cells to knock out genes at specific sites in the T cell genome; and

[0008] A donor template is introduced into T cells to knock the CAR gene into the specific site.

[0009] In some embodiments of the above method, the genes at the specific site include the TRAC gene, PD1 gene, CISH gene, and Regnase-1 gene.

[0010] In some embodiments of the above method, the specific sites include: TRAC sites, PD1 sites, CISH sites, and Regnase-1 sites.

[0011] In some embodiments of the above method, the gene editing tool is selected from the CRISPR / Cas system;

[0012] Optionally, the CRISPR / Cas system includes the Cas protein and sgRNA.

[0013] In some embodiments of the above method, the Cas protein includes any one of the following: spCas9, AsCas12a, or LbCas12a;

[0014] The sgRNA includes any one of the following sites: TRAC site, PD1 site, CISH site, and Regnase-1 site;

[0015] Optionally, the sgRNA sequence targeting the TRAC site is:

[0016] TRAC: 5'-AGAGTCTCTCAGCTGGTACACGG-3' (SEQ ID NO: 1);

[0017] The sgRNA sequence targeting the PD1 site is as follows:

[0018] PD1: 5'-CGACTGGCCAGGGCGCCTGT-3' (SEQ ID NO: 2);

[0019] The sgRNA sequence targeting the CISH site is as follows:

[0020] CISH: 5'-GGCGCATCCTCCTTAGGCAT-3' (SEQ ID NO: 3);

[0021] The sgRNA sequence targeting the Regnase-1 site is as follows:

[0022] Regnase-1: 5'-AAGGAGGTCTTCTCCTGCCG-3' (SEQ ID NO: 4).

[0023] In some embodiments of the above method, the donor template is plasmid DNA, dsDNA, or ssDNA;

[0024] Optionally, the donor template is dsDNA;

[0025] Alternatively, the donor template includes a left homologous arm sequence, a promoter sequence, a CAR gene, a transcription terminator sequence, and a right homologous arm sequence in the 5'-3' direction.

[0026] In some embodiments of the above method, the gene editing tool and the donor template are introduced into T cells in the form of a mixture via electroporation transfection;

[0027] Optionally, the Cas protein, sgRNA, and dsDNA are introduced into T cells in a mixture via electroporation transfection.

[0028] In some embodiments of the above method, the CAR gene comprises a nucleotide sequence encoding an extracellular antigen recognition domain, a nucleotide sequence encoding a hinge region, a nucleotide sequence encoding a transmembrane region, and a nucleotide sequence encoding an intracellular domain.

[0029] Optionally, the donor template further comprises a nucleotide sequence encoding a signal peptide, and the nucleotide sequence encoding the signal peptide is located between the promoter sequence and the nucleotide sequence encoding an extracellular antigen recognition domain;

[0030] Alternatively, the signal peptide is derived from CD8α;

[0031] Further optionally, the amino acid sequence of the signal peptide is shown in SEQ ID NO: 5.

[0032] In some embodiments of the above method, the extracellular antigen recognition domain targets one, two, or more of the following ligands: CD19, CD20, CD22, CD30, CD33, CD123, BCMA, SLAMF7, CD5, CD7, CLL1, NKG2D, DNAM1, NKp30, NKp44, NKp46, EGFR, EGFRv III, CEA, MUC1, MUC16, EphA2, IL13Rα2, CD70, CD171, PSMA, PSCA, ROR1, VEGFR2, cMet, FAP, GPC3, Claudin18.2, CD138, NKG2D, CD38, CD44v6, Lewis Y, mesothelin, HER2, GD2, L1-CAM, FR, and CAIX; optionally, the extracellular antigen recognition domain targets CLL1 or NKG2D ligands.

[0033] In some embodiments of the above method, the hinge region is derived from one or more of IgG1, IgG4, CD4, CD7, CD28, CD84, and CD8α; optionally, the hinge region is derived from CD8α; more preferably, the amino acid sequence of the hinge region is as shown in SEQ ID NO: 6; and / or

[0034] The transmembrane region is derived from one or more of CD3z, CD4, CD7, CD8α, CD28, CD80, CD86, CD88, 4-1BB, CD152, OX40, and Fc70; optionally, the transmembrane region is derived from CD8α or CD3z; more preferably, the amino acid sequence of the transmembrane region is as shown in SEQ ID NO: 7 or SEQ ID NO: 8.

[0035] In some embodiments of the above method, the intracellular domain includes an intracellular signal transduction region; optionally, it also includes a co-stimulatory signal transduction region.

[0036] In some embodiments of the above method, the intracellular signal transduction region is derived from one or more of CD3ζ, CD3γ, CD3δ, CD3ε, CCD5, CD22, CD79a, CD79b, FcRγ, FcRβ, CD66d, DAP10, DAP12, and Syk; optionally, the intracellular signal transduction region is derived from CD3ζ; more preferably, the amino acid sequence of the intracellular signal transduction region is as shown in SEQ ID NO: 9; and / or.

[0037] The co-stimulatory signal transduction region is derived from one, two, or more of CD2, CD3, CD7, CD27, CD28, CD30, CD40, CD83, CD244, 4-1BB, OX40, LFA-1, ICOS, LIGHT, NKG2C, NKG2D, DAP10, B7-H3, and MyD88; optionally, the co-stimulatory signal transduction region is derived from 4-1BB; more preferably, the amino acid sequence of the co-stimulatory signal transduction region is as shown in SEQ ID NO: 10.

[0038] In some embodiments of the above method, the promoter is selected from the SFFV promoter, CMV promoter, or EF1α promoter; optionally, the nucleotide sequence of the EF1α promoter is shown in SEQ ID NO: 11.

[0039] The nucleotide sequence of the transcription terminator sequence is shown in SEQ ID NO: 12.

[0040] In some embodiments of the above method, the nucleotide sequence encoding the T2A peptide is as shown in SEQ ID NO: 13; and / or

[0041] The marker gene sequence is an EGFP fluorescent protein gene or a GFP fluorescent protein gene; optionally, the nucleotide sequence of the GFP fluorescent protein gene is shown in SEQ ID NO: 14.

[0042] In some embodiments of the above method, the left and right homologous arm sequences for the TRAC site in the donor template are shown in SEQ ID NO: 15 and SEQ ID NO: 16, respectively; or

[0043] The left and right homologous arm sequences for the PD1 site in the donor template are shown in SEQ ID NO: 17 and SEQ ID NO: 18, respectively; or

[0044] The left and right homologous arm sequences for the CISH site in the donor template are shown in SEQ ID NO: 19 and SEQ ID NO: 20, respectively; or

[0045] The left and right homologous arm sequences for the Regnase-1 site in the donor template are shown in SEQ ID NO: 21 and SEQ ID NO: 22, respectively.

[0046] In some embodiments of the above method, the T cells are γδT cells.

[0047] In some embodiments of the above method, the method includes the following steps:

[0048] (1) Preparation of T cells

[0049] PBMC cells were revived, and TCRα / β magnetic beads were added for sorting. Cells sorted by magnetic beads were then activated with zoledronic acid.

[0050] (2) Introducing gene editing tools and donor templates into T cells

[0051] Three to four days after activation, a mixture containing gene editing tools and donor templates was introduced into T cells via electroporation. One day after electroporation, γδT complete medium was added and the cells were incubated. On the third day after electroporation, dasatinib and vitamin C were added to the γδT complete medium. CAR-T cells were harvested on the eleventh day after electroporation.

[0052] In some embodiments of the above method, the concentration of zoledronic acid is 5-10 μM;

[0053] The complete γδT culture medium contains 1-5 μM M3814 inhibitor and 10% fetal bovine serum or 10% human platelet lysate;

[0054] The concentration of dasatinib is 10-30 nM;

[0055] The concentration of vitamin C is 10-50 μM.

[0056] The present invention also provides a CAR-T cell, which is one of the following cells:

[0057] (1) CLL1-REG-γδT cells, which are CAR genes containing nucleotide sequences encoding CLL1 antibodies knocked into the Regnase-1 site of the genome of γδT cells;

[0058] (2) CLL1-CISH-γδT cells, which are CAR genes containing nucleotide sequences encoding CLL1 antibodies knocked into the CISH site of the γδT cell genome.

[0059] (3) CLL1-PD-1-γδT cells, which are CAR genes containing nucleotide sequences encoding CLL1 antibodies knocked into the PD1 site of the γδT cell genome;

[0060] (4) CLL1-TRAC-γδT cells, which are CAR genes containing nucleotide sequences encoding CLL1 antibodies knocked into the TRAC site of the genome of γδT cells.

[0061] (5) SuperγδT cells, which are CAR genes containing the NKG2D gene sequence knocked into the Regnase-1, CISH, PD1 or TRAC sites of the γδT cell genome.

[0062] In some embodiments of the CAR-T cells described above, the CAR gene is as shown in SEQ ID NO: 23 or SEQ ID NO: 24.

[0063] In some embodiments, the CAR-T cells described above are prepared using the methods described above.

[0064] This invention also provides the use of the above-mentioned CAR-T cells in the preparation of antitumor drugs;

[0065] Optionally, the drug is used to treat acute T-lymphoblastic leukemia (T-ALL), non-small cell lung cancer (NSCLC), acute myeloid leukemia (AML), hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and acute promyelocytic leukemia.

[0066] Compared with the prior art, the present invention achieves the following beneficial effects:

[0067] Currently, the use of lentiviruses to prepare CAR-T cells has the following drawbacks:

[0068] 1. High production costs, high quality inspection costs, and long processing time;

[0069] 2. Lentiviral integration of the CAR gene is a random insertion, which poses a risk of tumorigenesis;

[0070] 3. CAR-T cells prepared by lentiviruses have the problem of uneven CAR expression;

[0071] 4. CAR gene site-specific integration into γδT has a low positive rate and low MFI (mean fluorescence intensity).

[0072] To address the drawbacks of both viral use and random integration, this invention utilizes CRISPR-Cas9 technology to develop non-viral CAR-γδT cells with CAR gene-targeted integration, and demonstrates that the method for preparing CAR-T cells in this invention has the following advantages.

[0073] 1. This invention utilizes non-viral site-specific integration technology to prepare CAR-T cells, avoiding the use of viruses, which can significantly reduce production costs and reduce quality control procedures.

[0074] 2. Non-viral site-specific integration technology for CAR-T cell preparation can reduce the risk of tumorigenesis due to random insertion.

[0075] 3. Non-viral site-specific integration technology can improve the uniformity of CAR expression in CAR-T cell preparation.

[0076] 4. CARγδT cells prepared by non-viral site-specific integration technology improved the CAR expression intensity of CARγδT cells.

[0077] The technical solution of the present invention will be further described in detail below with reference to the accompanying drawings and embodiments. Attached Figure Description

[0078] Figure 1 is a schematic diagram of the non-virus targeted integration principle of the present invention.

[0079] Figure 2 is a schematic diagram of the preparation process of CLL1 CARγδT cells according to the present invention.

[0080] Figure 3 shows the positive rate and MFI (mean fluorescence intensity) of CLL1 CARγδT cells prepared by lentiviral and non-viral site-directed integration methods according to the present invention. In Figure 3, CLL1-LV and CLL1-TRAC represent CLL CARγδT cells prepared by lentiviral infection (Comparative Example 1) and CLL1-TRAC-γδT cells prepared by non-viral site-directed integration technology (Example 1), respectively.

[0081] Figure 4 shows the expansion curves of CLL1 CARγδT cells prepared by different methods.

[0082] Figure 5 shows the viability of CLL1 CARγδT cells prepared by different methods.

[0083] Figure 6 shows the γδ2+ expression ratio of CLL1 CARγδT cells prepared by different methods.

[0084] Figure 7 shows the proportion of memory cells in CLL1 CARγδT cells prepared by different methods. In Figure 7, the bars in each column represent CD62L-CD45RA+, CD62L-CD45RA-, CD62L+CD45RA-, and CD62L+CD45RA+, respectively, from top to bottom.

[0085] Figure 8 shows the killing effect of CLL1 CARγδT cells prepared by different methods on AML tumor cell lines. In Figure 8, each bar from left to right represents UTD cells (untransduced CAR T cells), CLL1-LV cells, and CLL1-TRAC cells, respectively.

[0086] Figure 9 shows the multi-round stimulation expansion capacity of CLL1 CARγδT cells prepared by different methods. In Figure 9, each bar from left to right represents UTD cells (untransduced CAR T cells), CLL1-LV cells, and CLL1-TRAC cells, respectively.

[0087] In Figures 4-9, CLL1-LV and CLL1-TRAC represent CLL CARγδT cells prepared by lentiviral infection (Comparative Example 1) and CLL1-TRAC-γδT cells prepared by non-viral site-directed integration technology (Example 1), respectively. UTD-γδT cells represent γδT cells that have not been transduced with CAR.

[0088] Figure 10 shows the CAR expression in CLL1 CARγδT cells integrated at different sites.

[0089] Figure 11 shows the expansion curves of CLL1 CARγδT cells integrated at different sites during the culture phase.

[0090] Figure 12 shows the viability of CLL1 CARγδT cells integrated at different sites during the culture phase.

[0091] Figure 13 shows the expression ratios of CD3 and γδ2 in CLL1 CARγδT cells integrated at different sites during the culture phase.

[0092] Figure 14 shows the proportion of CCR7+ memory cells in CLL1 CARγδT cells integrated at different sites at harvest. In Figure 14a, the bars in each column represent, from top to bottom, CCR7-CD45RA+; CCR7-CD45RA-; CCR7+CD45RA- and CCR7+CD45RA+. In Figure 14b, the bars in each column represent, from top to bottom, CD62L-CD45RA+; CD62L-CD45RA-; CD62L+CD45RA- and CD62L+CD45RA+.

[0093] Figure 15 shows a comparison of the short-term killing ability of CAR γδT cells integrated at different sites. In Figure 15, each bar represents γδT cells, CLL1-TRAC cells, CLL1-PD1 cells, CLL1-REG cells, and CLL1-CISH cells from left to right.

[0094] Figure 16 shows the effector cell proliferation and killing in each group during multiple rounds of stimulation. In Figure 16b, each bar represents, from left to right, UTD cells (untransduced CAR T cells), CLL1-TRAC cells, CLL1-PD1 cells, CLL1-REG cells, and CLL1-CISH cells.

[0095] Figure 17 is a schematic diagram of the preparation process of SuperγδT cells according to the present invention.

[0096] Figure 18 shows the viability of SuperγδT cells during the culture phase.

[0097] Figure 19 shows the expansion of SuperγδT cells during the culture phase.

[0098] Figure 20 shows the γδ2 purity of SuperγδT cells during the culture phase.

[0099] Figure 21 shows the positive rate of SuperγδT cells at harvest.

[0100] Figure 22 shows the short-term killing effect of SuperγδT cells on AML tumor cell lines. In Figure 22, each bar from left to right represents UTD-γδT cells (γδT cells not transduced with CAR) and SuperγδT cells, respectively.

[0101] In Figures 17-22, SuperγδT represents SuperγδT cells prepared by knocking in a CAR gene containing the NKG2D gene sequence into the TRAC site of the genome of γδT cells using a non-viral site-directed integration technique (Example 4). Detailed Implementation

[0102] The following further describes this application: In this invention, unless otherwise stated, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. Furthermore, the terms and laboratory procedures related to protein and nucleic acid chemistry, molecular biology, cell and tissue culture, microbiology, and immunology used herein are all widely used terms and routine procedures in their respective fields. Meanwhile, to better understand this invention, definitions and explanations of relevant terms are provided below.

[0103] In this application, the terms "gene editing" and "gene editing technology" have their common meaning in the art, referring to a new technology for site-specific modification of the genome. This technology allows for precise targeting to a specific site on the genome, where target DNA fragments can be cut, or target gene fragments can be knocked in or knocked out. As a molecular biology technique, gene editing technology enables precise modification of chromosomes, thereby altering the existing functions of cells. Compared to cell lines commonly used in basic research, T cells, as primary cells, are not particularly unique except for their inability to proliferate long-term, and can also be edited using gene editing technology. Currently, there are three main gene editing technologies: zinc finger nuclease (ZFN) technology, transcription activator-like effector nuclease (TALEN) technology, and RNA-guided CRISPR / Cas nuclease technology. Compared to traditional gene targeting techniques, this new gene editing technology retains the characteristic of site-specific modification, can be applied to more species and cells, is more efficient, has a shorter construction time, and is less costly.

[0104] In this application, the terms "CRISPR / Cas technology" and "CRISPR / Cas system" have their common meaning in the art. CRISPR stands for clustered regularly interspaced short palindromic repeats / CRISPR-associated proteins, an acquired immune system found in most bacteria and all archaea that can directionally cleave foreign gene fragments. Different types of CRISPR / Cas systems have been discovered, with the second type being relatively simple, consisting primarily of the Cas9 protein and guide RNA (gRNA). Compared to earlier ZFN and TALEN technologies, CRISPR / Cas offers advantages such as low off-target rates, high efficiency, affordability, and wide applicability. Furthermore, some literature reports that CRISPR hybrid RNA-DNA (chRDNA) guidance technology significantly improves the specificity of the Cas9 protein compared to whole RNA guidance technology, thereby achieving high levels of intended genome editing in cells and minimizing off-target time.

[0105] In this application, the term "Chimeric Antigen Receptor" (CAR) is a core component of CAR cell therapy drugs, which may include an extracellular antigen recognition domain (e.g., a portion that binds to tumor-associated antigens (TAAs)), a hinge region, a transmembrane region, and an intracellular domain. CAR-T (Chimeric Antigen Receptor T) cell immunotherapy is considered one of the most promising approaches to combating cancer. CAR-T cells utilize genetic modification to enable T cells to express CAR proteins. These CAR proteins are capable of recognizing intact proteins on the cell membrane surface without antigen presentation, thereby activating and functionally affecting T cells.

[0106] In this application, the term "extracellular antigen recognition domain" refers to the antigen recognition domain (ARD). CAR cell therapy products (such as CAR-T cells) rely on extracellular antigen recognition domains to specifically recognize and / or bind to target antigens expressed by tumor cells. To date, antigen recognition domains are derived from the single-chain variable fragment (scFv) of antibodies, or from receptor-ligand interactions, TCR mimics, and variable lymphocyte receptors (VLRs). The most common source to date is the antibody scFv segment, which includes the antibody heavy chain variable region (VH region) and light chain variable region (VL region) linked by a peptide chain, such as the 18-amino acid linker sequence GSTGSGSGKPGSGEGSTKG.

[0107] In this application, the term "hinge region" refers to the connecting segment that acts between the extracellular antigen recognition domain and the transmembrane domain. This region allows the CAR to recognize the antigen by providing a certain range of motion to the antigen recognition domain. Currently used hinge regions are mainly derived from one or more of IgG1, IgG4, CD4, CD7, CD28, CD84, and CD8α. In addition, typical hinge regions also contain residues that participate in CAR dimerization, which helps to enhance antigen sensitivity.

[0108] In this application, "transmembrane region" refers to a transmembrane domain connecting the intracellular and extracellular components of the CAR structure. Different transmembrane domains can affect CAR expression and stability to some extent, but do not directly participate in signal transduction; however, they can enhance downstream signal transduction through interactions. The transmembrane region may be derived from one or more of CD3z, CD4, CD7, CD8α, CD28, CD80, CD86, CD88, 4-1BB, CD152, OX40, and Fc70.

[0109] In this application, the term "intracellular domain" includes intracellular signal transduction regions and may also include co-stimulatory signal transduction regions.

[0110] In this application, the term "intracellular signal transduction region" refers to the activation of at least one normal effector function of an immune effector cell responsible for expressing CAR. The intracellular signal transduction region may originate from one or more of CD3ζ, CD3γ, CD3δ, CD3ε, CD5, CD22, CD79a, CD79b, FcRγ, FcRβ, CD66d, DAP10, DAP12, and Syk.

[0111] In this application, the term "co-stimulatory signal transduction region" is used because, in addition to antigen-specific signal stimulation, many immune effector cells require co-stimulation to promote cell proliferation, differentiation, and survival, as well as to activate effector functions. In some embodiments, the CAR may further include one or more co-stimulatory signal transduction regions, wherein the co-stimulatory signal transduction regions may be derived from one, two, or more of CD2, CD3, CD7, CD27, CD28, CD30, CD40, CD83, CD244, 4-1BB, OX40, LFA-1, ICOS, LIGHT, NKG2C, NKG2D, DAP10, B7-H3, and MyD88.

[0112] In this application, the term "guide peptide" refers to a short peptide preceding an extracellular antigen recognition domain (such as the scFv sequence), which guides the export of intracellularly synthesized recombinant proteins to the extracellular space. Commonly used guide peptides include the human CD8α signal peptide or the human GM-CSF receptor α signal peptide.

[0113] In this application, the term "chimeric antigen receptor-T cell" generally refers to CAR-T cells formed by transfecting chimeric antigen receptors (CARs) into T cells. These cells activate T cells by binding to specific antigens on the surface of tumor cells using an antigen-antibody binding mechanism, specifically recognizing and killing tumors (Jackson HJ et al., Nature Reviews Clinical Oncology, 2016, 13(6):370-383). CAR-T cells recognize tumor antigens without being restricted by human leukocyte antigens (HLA), effectively preventing immune escape by tumor cells through downregulation of major histocompatibility complex (MHC) molecule expression (Fesnak AD et al., Nature Reviews Cancer, 2016, 16(9):566-581).

[0114] In this application, the term "comprising" generally means including the explicitly specified features, but does not exclude other elements.

[0115] In this application, the term "about" generally refers to a range of fluctuations acceptable to a person skilled in the art above or below a specified value, such as a variation within ±0.5% to 10%, for example, a variation within a range of 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10% above or below a specified value.

[0116] This invention utilizes non-viral site-directed integration technology to prepare enhanced chimeric antigen receptor-T cells. Specifically, it employs the CRISPR-Cas9 gene knock-in method to site-directly knock exogenous groups into T cells.

[0117] CRISPR-Cas9 knock-in (KI) refers to the process where the Cas9 restriction enzyme cuts double-stranded DNA, simultaneously providing a DNA repair template highly homologous to the target gene. The organism then initiates the High-Homogeneous Recombination (HDR) repair pathway, inserting a foreign DNA fragment into the gene at a specific site. The foreign gene in KI can be a protein-coding gene, a DNA element involved in gene regulation, or a non-functional DNA sequence. This repair pathway requires the introduction of a DNA repair template highly homologous to the sequences immediately upstream and downstream of the target editing site, a specific gRNA, and the Cas9 nuclease into the cell. In the presence of a highly homologous DNA template, the HDR mechanism can precisely insert a DNA fragment into a specific genomic site through homologous recombination.

[0118] In this invention, Cas9 protein and sgRNA targeting a specific site are co-transformed into T cells with a donor template (e.g., dsDNA) containing a CAR group. The transfected sgRNA guides the Cas9 protein to a specific site on the T cell, cleaves the specific site, introduces a DNA double-strand break at the specific site, knocks out the gene at the specific site, and then uses homologous recombination to knock the CAR gene into the specific site, thereby achieving targeted knock-in of the CAR gene into the T cell gene, thus obtaining CAR-T cells.

[0119] In this invention, the sgRNA is designed based on the insertion site sequence of T cells. In this invention, the insertion site refers to any nucleotide site in a gene that a person skilled in the art would like to knock into the CAR gene, such as the TRAC site, PD1 site, Regnase-1 site, or Roquin-1 site.

[0120] In this invention, the donor template contains homologous arm sequences at both its 5' and 3' ends, which are homologous to the T-cell targeting gene. The left homologous arm of the template DNA is homologous to the 5' end sequence of the DNA nick, and the right homologous arm is homologous to the 3' end sequence of the DNA nick. These homologous arm sequences can mediate homologous recombination between the CAR gene and the T-cell targeting gene, thereby achieving CAR gene knock-in. In this invention, the CAR gene may contain nucleotide sequences encoding an extracellular antigen recognition domain, a hinge region, a transmembrane region, and an intracellular domain. The extracellular antigen recognition domain targets CD19, CD20, CD22, CD30, CD33, CD123, BCMA, SLAMF7, CD5, CD7, CLL1, NKG2D, DNAM1, NKp30, NKp44, NKp46, EGFR, EGFRv III, CEA, MUC1, MUC16, EphA2, IL13Rα2, CD70, CD171, PSMA, PSCA, ROR1, VEGFR2, cMet, FAP, GPC3, Claudin18.2, CD138, NKG2D, CD38, CD44v6, Lewis... One, two, or more of Y, mesothelin, HER2, GD2, L1-CAM, FR, and CAIX; optionally, the extracellular antigen recognition domain targets CLL1 or NKG2D ligands.

[0121] In this invention, the donor template is selected from plasmid templates, double-stranded DNA templates, linear single-stranded DNA templates, and circular single-stranded DNA templates. In other words, this invention does not have special requirements for the form of the donor template; any form of template can be selected according to specific experimental needs to achieve efficient gene knock-in.

[0122] In this invention, the donor template consists of the target gene to be introduced and homologous sequences (homologous arms) upstream and downstream of the target sequence. The length and position of the homologous arms are determined by the size of the edited sequence. The donor template can insert the CAR gene into the target site through homologous recombination, thereby precisely inserting a DNA sequence into a specific site.

[0123] In this invention, transfection (electroporation) is performed using a mixture of mRNA and sgRNA encoding the Cas9 protein. Alternatively, the Cas9 protein can be used instead of the Cas9 mRNA. The Cas9 protein can be obtained through expression and purification in bacteria or eukaryotic expression cells. In some embodiments, electroporation is performed using an RNP complex formed from the Cas9 protein and sgRNA. The RNP complex can be obtained by directly mixing and incubating the Cas9 protein and sgRNA, or by mixing them in a specific buffer (such as an electroporation buffer).

[0124] The present invention is further illustrated below by way of examples. These examples are for illustrative purposes only and not for limiting the invention. Simple modifications made to the present invention based on its essence are all within the scope of protection claimed by the present invention. The present invention is further described below with reference to examples:

[0125] Example 1: Preparation of CLL1 CARγδT

[0126] Figure 1 is a schematic diagram of the non-viral site-specific integration principle of the present invention. In Figure 1, the CRISPR / Cas9 system is introduced into T cells, and a double-strand DNA break is generated at the Gene X Locus in the T cell genome via CRISPR-mediated DSB (CRISPR-mediated Double-Strand Break, DSB) to knock out the gene at the Gene X Locus in the T cell genome; and

[0127] Donor DNA (containing the CAR gene) is introduced into T cells to knock the CAR gene into the X gene locus, thereby obtaining CAR-T cells in which the CAR gene is specifically integrated into the X gene locus in the genome of the T cells.

[0128] In Figure 1, the gene at the X gene locus refers to the TRAC gene, PD-1 gene, Regnase-1 gene, or CISH gene; the X gene locus refers to the TRAC locus, PD-1 locus, Regnase-1 locus, or CISH locus.

[0129] In this embodiment, CLL1 CARγδT cells were prepared according to the flowchart shown in Figure 1.

[0130] CLL1 CAR site integration sequences were designed at the TRAC, PD1, CISH, and Regnase-1 sites to prepare CLL1 CARγδT cells.

[0131] 1. Design and preparation of dsDNA

[0132] dsDNA is a double-stranded DNA with closed ends, prepared by GenScript.

[0133] The amino acid sequence of the chimeric antigen receptor CD8a-CLL1-8TM-BBζ:

[0134] MALPVTALLLPLALLLHAARPDIQMTQSLSSSLSASVGDRVTITCKASQDVSTAVAWYQQKPGKSPKLLIYSASYRYTGVPDRFSGSGSGTDFTFTISSVQPEDFAVYYCQQHYSTPLTFGAGTKLEIKGGGGSGGGGSG GGGSQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYVMHWVRQAPGQGLEWMGYINPYNDGTKYNEKFKGRVTLTSDTSTSTAYMELSSLRSEDTAVYYCARGYYWYDEGHAMDSWGQGTLVTVSSTTTPAPRPPTPAP TIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (sequentially CD8α signal peptide, CLL1 extracellular sequence, CD8 hinge region sequence, CD8 transmembrane region sequence, 4-1BB co-stimulatory signal transduction region, CD3ζ intracellular signal transduction region (SEQ ID NO: 25))

[0135] The nucleotide sequence encoding the chimeric antigen receptor CD8a-CLL1-8TM-BBζ (SEQ ID NO: 23):

[0136] Starter sequence:

[0137] Transcription terminator sequence:

[0138] TRAC site homologous arm sequence: LHA:

[0139] RHA:

[0140] PD1 site homologous arm sequence: LHA:

[0141] RHA:

[0142] CISH site homologous arm sequence: LHA:

[0143] RHA:

[0144] Regnase-1 site homologous arm sequence: LHA:

[0145] RHA:

[0146] dsDNA-1 corresponding to CD8a-CLL1-8TM-BBζ targeting the TARC site was synthesized. The donor template included a left homologous arm sequence (SEQ ID NO: 15), a promoter sequence (SEQ ID NO: 11), a nucleotide sequence encoding CD8a-CLL1-8TM-BBζ (SEQ ID NO: 23), a transcription terminator sequence (SEQ ID NO: 12), and a right homologous arm sequence (SEQ ID NO: 16) in the 5'-3' direction.

[0147] dsDNA-2 corresponding to CD8a-CLL1-8TM-BBζ targeting the PD1 site was synthesized. The donor template included a left homologous arm sequence (SEQ ID NO: 17), a promoter sequence (SEQ ID NO: 11), a nucleotide sequence encoding CD8a-CLL1-8TM-BBζ (SEQ ID NO: 23), a transcription terminator sequence (SEQ ID NO: 12), and a right homologous arm sequence (SEQ ID NO: 18) in the 5'-3' direction.

[0148] dsDNA-3 corresponding to CD8a-CLL1-8TM-BBζ targeting the CISH site was synthesized. The donor template included a left homologous arm sequence (SEQ ID NO: 19), a promoter sequence (SEQ ID NO: 11), a nucleotide sequence encoding CD8a-CLL1-8TM-BBζ (SEQ ID NO: 23), a transcription terminator sequence (SEQ ID NO: 12), and a right homologous arm sequence (SEQ ID NO: 20) in the 5'-3' direction.

[0149] dsDNA-4 corresponding to CD8a-CLL1-8TM-BBζ targeting the Regnase-1 site was synthesized. The donor template included a left homologous arm sequence (SEQ ID NO: 21), a promoter sequence (SEQ ID NO: 11), a nucleotide sequence encoding CD8a-CLL1-8TM-BBζ (SEQ ID NO: 23), a transcription terminator sequence (SEQ ID NO: 12), and a right homologous arm sequence (SEQ ID NO: 22) in the 5'-3' direction.

[0150] Guide RNA N20 sequence:

[0151] TRAC: 5'-AGAGTCTCTCAGCTGGTACACGG-3' (SEQ ID NO: 1)

[0152] PD1:5'-CGACTGGCCAGGGGCGCCTGT-3'(SEQ ID NO: 2)

[0153] CISH:5'-GGCGCATCCTCCTTAGGCAT-3'(SEQ ID NO: 3)

[0154] Regnase-1:5'-AAGGAGGTCTTCTCCTGCCG-3' (SEQ ID NO: 4)

[0155] 2. Cell culture:

[0156] The cell culture process is shown in Figure 2, including: sorting and activation; non-viral site-specific integration; amplification; and harvesting.

[0157] In brief:

[0158] On Day 4, PBMC cells were resuscitated and sorted using TCRα / β magnetic beads. Cells sorted by magnetic beads were activated with zoledronic acid to form γδT cells. Four days after activation (Day 0), a mixture containing gene editing tools and donor templates was introduced into γδT cells via electroporation. One day after electroporation (Day 1), complete γδT culture medium was added and the cells were incubated. On Day 3 after electroporation (Day 3), dasatinib and vitamin C were added to the complete γδT culture medium. On Day 5, Day 7, and Day 9 during the culture process, the proportion of CD3, Vδ2+, and CAR positivity were detected by flow cytometry. CAR-T cells were harvested on Day 11 after electroporation (Day 11). Cell memory type was detected by flow cytometry, cell killing experiments were performed, and in vitro antigen multi-round stimulation experiments were conducted. The remaining cells were cryopreserved using a programmed freezing system.

[0159] 2.1 Cell sorting activation

[0160] 1. Cell sorting: Take the frozen or freshly isolated PBMCs out of the liquid nitrogen tank, quickly transfer them through the transfer window to the cell chamber, and immediately place them in a 37°C water bath to thaw;

[0161] 2. Take a 50ml centrifuge tube, gently mix the melted cell suspension, mix the cells, and take a sample for counting;

[0162] 3. Collect cells, sample for flow cytometry analysis, centrifuge at 300g for 10 minutes, and remove the supernatant;

[0163] 4. Resuspend cells in Miltenyi sorting buffer (EDTA / DPBS + 1% HSA (human serum albumin)), resuspend cells according to the reference dosage of CD4 magnetic beads and CD8 magnetic beads, or αβT sorting kit, and add sorting magnetic beads;

[0164] 5. After mixing, incubate in a refrigerator at 2-8℃ for 15 minutes;

[0165] 6. Add sorting buffer to resuspend the cells, centrifuge at 300g for 10 minutes, and remove the supernatant;

[0166] 7. Follow the 0.5mL buffer / 10 8 Resuspend the cells in sorting solution; (add 500 μL if less than 500 μL);

[0167] 8. Separate negative and positive cells using LS columns and magnetic racks;

[0168] Centrifuge at 300g for 8 minutes and discard the supernatant;

[0169] 10. Count the isolated negative and positive cells separately, according to (2-3) × 10⁻⁶. 6 Cells were resuspended at a density of 1 / ml by adding an appropriate amount of γδT complete medium (containing 5 μM M3814, 10% FBS or 10% HPL) and cultured in a CO2 incubator; 5-10 μM beryllium phosphate was added to the γδT cell medium for activation.

[0170] 2.2 Cell electroporation:

[0171] Three to four days after cell activation, the cells were pipetted and counted. An electroporation mixture was prepared according to the LONZA electroporation system, at a concentration of (0.8–1) × 10⁶ cells / cell. 6 The electroporation system corresponding to each cell is as follows:

[0172] Depending on the insertion site, different sgRNAs and different dsDNAs are selected. For example, if the insertion site is a TRAC site, then the sgRNA is 5'-AGAGTCTCTCAGCTGGTACACGG-3' (SEQ ID NO: 1) and the dsDNA is 1.

[0173] After preparation, incubate at room temperature for 15 minutes;

[0174] According to the required cell quantity for each group in the RNP preparation table, add (0.8–1) × 10⁻⁶ cells to each group. 6 One cell (resuspended in 10 μL with P3 buffer);

[0175] Transfer the material to the electro-spinning strips, avoiding the formation of air bubbles, and select the LONZA EH100 electro-spinning instrument program to complete the electro-spinning.

[0176] Prepare γδT complete medium containing 1–5 μM M3814 (an effective and selective inhibitor of DNA-dependent protein kinase (DNA-PK), commercially available), 10% FBS (fetal bovine serum) or 10% HPL (human platelet lysate), add 100 μL to each well, and incubate at 37°C for 15 min.

[0177] After incubation, transfer to a 96-well plate and add γδT complete medium containing 5 μM M3814, 10% FBS or 10% HPL to each well.

[0178] 1.3 Cell Culture:

[0179] (1) 24 hours after electroporation, fresh culture medium was added and the cells were transferred to 48-well or 24-well plates according to the cell density;

[0180] (2) On Day 3 after electroporation, 10-30 nM Dasatinib and 10-50 μM Vitamin C were added to the culture medium. The cells were passaged according to the cell density to maintain the cell density at 0.5 E6 to 3 E6 / mL.

[0181] (3) During the culture process (such as Day 5, Day 7 and Day 9 after electroporation), the cell density, viability, positivity rate and purity were detected (e.g. CD3 ratio, Vδ2+ ratio and CAR positivity rate).

[0182] 2.4 Cell harvesting: Cells were harvested on Day 11 after electroporation.

[0183] CLL1-REG-γδT cells were obtained, which are CAR genes containing nucleotide sequences encoding CLL1 antibodies knocked into the Regnase-1 site of the γδT cell genome (SEQ ID NO: 23).

[0184] CLL1-CISH-γδT cells are CAR genes (SEQ ID NO: 23) with a nucleotide sequence encoding a CLL1 antibody knocked into the CISH site of the γδT cell genome.

[0185] CLL1-PD-1-γδT cells are CAR genes (SEQ ID NO: 23) with a nucleotide sequence encoding a CLL1 antibody knocked into the PD1 site of the γδT cell genome.

[0186] CLL1-TRAC-γδT cells are CAR genes (SEQ ID NO: 23) containing a nucleotide sequence encoding a CLL1 antibody, which are knocked into the TRAC site of the γδT cell genome.

[0187] Comparative Example 1: CLL1 CARγδT cells were prepared by lentiviral infection.

[0188] 1. Construction of lentiviral vectors

[0189] The CD8a-CLL1-8TM-BBζCAR structure was constructed into modified empty lentiviral vectors (manufacturer: SBI, catalog numbers: CD500-CD800, such as the modified resistance described in Example 1 of WO2021 / 121227) to obtain CAR expression vectors. These CAR expression vectors, along with three packaging plasmids, were then transfected into 293T cells. After collection and purification, functional lentiviral vectors were obtained. The three packaging plasmids were pMD2.G (purchased from Biovector, product number Biovector012259), pMDLg / pRRE (purchased from Biovector, product number Biovector012251), and pRSV-Rev (purchased from Biovector, product number Biovector012253).

[0190] 2. CLL1 CARγδT cells were prepared by lentivirus transduction.

[0191] The transduction experiment was conducted according to conventional methods known to those skilled in the art. The transduction steps are briefly described below:

[0192] 1) Sorting T cells

[0193] Peripheral blood mononuclear cells (PBMCs) are isolated from human apheresis cells, and then T cells are sorted from the PBMCs.

[0194] 2) Activation treatment of T cells

[0195] The isolated T cells were resuspended in complete T cell culture medium (containing 5 μM M3814, 10% FBS or 10% HPL) to a final concentration of (1–3) × 10⁻⁶. 6 Cells / ml, 1ul beads / 1×10 6 Cells were stimulated with CD3 / CD28 magnetic beads, mixed well, and then placed in an incubator for incubation at 37°C + 5% CO2 for at least 24 hours.

[0196] 3) Lentiviral transduction of T cells

[0197] Remove activated T cells from the culture and resuspend them in X-VIVO15 medium containing 8 μg / ml polybrene. Mix well to obtain a cell suspension, and then adjust the concentration of each cell suspension to 2 × 10⁻⁶ cells per 800 μL of cell suspension. 6 Slowly add 200 μL of lentiviral vector to the cells, mix well, place in a well plate, and incubate in an incubator at 37°C + 5% CO2 for at least 4-6 hours.

[0198] 4) Expansion and culture of transduced T cells

[0199] The transduced cells were removed and expanded in complete T-cell culture medium, passaged every other day to maintain a cell density of (0.8–2) × 10⁻⁶ cells. 6 Cells / ml, for use in subsequent examples.

[0200] After infecting γδT cells with lentiviruses containing the CD8a-CLL1-8TM-BBζCAR structure, CLL1 CARγδT cells were obtained and named CLL1-LV cells.

[0201] Example 2 compares the activity of CLL1 CARγδT cells prepared in Example 1 and Comparative Example 1.

[0202] I. Activity detection:

[0203] (1) Phenotypic detection:

[0204] During cell culture, a certain amount of cells are taken for testing. Antibodies include anti-CLL1, anti-VD2, anti-CD3, anti-CD45RA, anti-CD62L, anti-CCR7, etc.

[0205] After incubation with flow cytometry antibody, the cells were washed with FACS buffer (PBS + 0.25% BSA) and the expression of cell surface markers was detected by flow cytometry.

[0206] (2) Experimental method for determining cell expansion curves

[0207] 1. Preparation of cell suspension: The cell cultures to be tested (e.g., γδT cells, CLL1-LV cells prepared in Comparative Example 1, and CLL1-TRAC cells prepared in Example 1) were pipetted to prepare a single-cell suspension, and the cell concentration was adjusted to 1-3 M / mL (i.e., (1-3) × 10⁻⁶). 6 (cells / mL).

[0208] 2. Staining: Take 20 μL of cell suspension, add 20 μL of AOPI staining solution (commercially available), mix gently, and add 20 μL to a cell counting chamber.

[0209] Detection: Insert the cell counting chamber into the CountStar counter to detect cell density. Cell count = cell density × cell culture volume.

[0210] (3) Experimental methods for determining cell viability during the cell culture stage

[0211] 1. Preparation of cell suspension: The cell culture to be tested (e.g., γδT cells, CLL1-LV cells prepared in Comparative Example 1 and CLL1-TRAC cells prepared in Example 1) was pipetted to prepare a single-cell suspension, and the cell concentration was adjusted to 1-3 M / mL.

[0212] 2. Staining: Take 20 μL of cell suspension, add 20 μL of AOPI staining solution (commercially available), mix gently, and add 20 μL to a cell counting chamber.

[0213] Detection: Insert the cell counting chamber into the CountStar counter to detect cell viability.

[0214] (4) Experimental method for determining the γδ2+ expression ratio in CARγδT cells

[0215] 1. Cell preparation

[0216] Take an appropriate amount of cell suspension (e.g., UTD-γδT cells (γδT cells not transduced with CAR), CLL1-LV cells prepared in Comparative Example 1, and CLL1-TRAC cells prepared in Example 1), wash the cells 2-3 times with PBS, resuspend the cells in PBS containing 0.25% BSA (bovine serum albumin), and adjust the cell concentration to a suitable range, usually 1×10⁻⁶. 6 -1×10 7 Cells / mL.

[0217] 2. Staining

[0218] Add 1 μL of γδ2TCR antibody to each sample, incubate at 4°C in the dark for half an hour, and then wash the cells 2-3 times with PBS containing 0.25% BSA to remove unbound antibodies.

[0219] 3. Flow cytometry detection

[0220] The prepared cell suspension was analyzed by flow cytometry to detect the γδ2+ expression ratio of CARγδT cells.

[0221] (5) Experimental method for determining the proportion of memory cells

[0222] 1. Cell preparation

[0223] Take an appropriate amount of cell suspension (e.g., γδT cells, CLL1-LV cells prepared in Comparative Example 1, and CLL1-TRAC cells prepared in Example 1), wash the cells 2-3 times with PBS, resuspend the cells in PBS containing 0.25% BSA (bovine serum albumin), and adjust the cell concentration to a suitable range, usually 1×10⁻⁶. 6 -1×10 7 Cells / mL.

[0224] 2. Staining

[0225] Add 1 μL of CD45RA antibody and CD62L antibody to each sample, incubate at 4 degrees Celsius in the dark for half an hour, and then wash the cells 2-3 times with PBS containing 0.25% BSA to remove unbound antibodies.

[0226] 3. Flow cytometry detection

[0227] The prepared cell suspension was analyzed by flow cytometry to determine the proportion of memory cells.

[0228] (6) External killing (short-term):

[0229] 1. Target cell plate

[0230] 1.1 Target cell preparation:

[0231] 1.1.1 The target cells are in good logarithmic growth phase with a cell viability of over 85%.

[0232] 1.1.2 Count the target cells according to standard cell counting procedures, and take 2 × 10⁻⁶ cells. 6 Transfer the target cells to a 15ml centrifuge tube, centrifuge at 300g for 8 minutes, remove the supernatant, and resuspend the target cells in T0 medium (X-Vivo medium + 5% FBS) until the cell density is 2×10⁻⁶ cells / mL.5 per ml.

[0233] 1.1.3 Transfer the diluted target cells into a sterile sample loading tray and use a pipette to add the target cells into a 96-well plate with a black bottom, 50 μL / well.

[0234] 1.2 Effector cell plate

[0235] 1.2.1 Effector cell preparation: The cell dosage was calculated according to effector-to-target ratios of 1:3, 3:1, and 1:1, respectively, and was 1 / 9 × 10⁻⁶ cells. 4 1, 3×10 4 1×10 4 Count the effector cells and take the required number of γδT cell samples (CLL1-REG-γδT cells, CLL1-CISH-γδT cells, CLL1-PD-1-γδT cells, CLL1-TRAC-γδT cells, and CLL-LV cells) into a 15ml centrifuge tube, centrifuge at 300g for 8min, and discard the supernatant.

[0236] 1.2.2 γδT cells were resuspended in T0 medium (X-vivo + 5% FBS), and the effector cell density was adjusted according to the effector-target ratio. Three effector-target ratios were set: 1:3, 3:1, and 1:1.

[0237] 1.2.3 Add effector cells to the well plates at effector-to-target ratios of 1:3, 3:1, and 1:1, 50 μL / well.

[0238] 1.3 Setting up the target cell control group

[0239] Add 50 μL of target cells and 50 μL of T0 medium (X-vivo + 5% FBS) to the wells of the target cell control group to make the total culture volume of the target cell control group consistent with the total culture volume of the co-culture experimental group.

[0240] 2. Detect luc value

[0241] 2.1 Cell co-culture: Place the 96-well plate with the added samples in a CO2 incubator and co-culture for 18-24 hours.

[0242] 2.2 Adding the detection reagent: Melt steadyglo luciferase (commercially available) at room temperature in the dark. Dilute the steadyglo required for the experiment with PBS 3 times and mix well. Add 50 μL to each well and place on a 96-well plate shaker. Shake at 100 rpm for 15 min in the dark.

[0243] 2.3 Instrumental Detection: Turn on the multi-mode microplate reader and computer software. Place the shaken 96-well plate into the multi-mode microplate reader and detect the luciferase fluorescence intensity. Remove the 96-well plate and turn off the instrument and computer.

[0244] 3. Calculation of cell killing activity

[0245] After obtaining the luc values ​​of all wells, calculate the cytotoxic activity using the following formula.

[0246] Cell-killing activity = (average luc value of target cells alone - luc value of co-culture wells) / average luc value of target cells alone × 100%

[0247] (7) External killing (long duration):

[0248] Cell killing experimental plate

[0249] 1. Effector cells in each group were co-cultured with target cells (HL60, THP1) at an effector-to-target ratio of 1:10. 0.15 mL of 8E5CAR+ effector cells and 1 mL of 1.2E6 / mL target cells were added to 12-well plates, and the volume was brought up to 3 mL with T0 medium.

[0250] 2. Detect luc value

[0251] 2.1 Luc values ​​were measured on day 1 / day 2 / day 3 / day 4 / day 5. For each measurement, 100 μL of cell suspension from a 12-well plate was transferred to a 96-well plate.

[0252] 2.2 Adding the test reagent: Melt steady glo at room temperature in the dark. Dilute the steady glo required for the experiment with PBS 3 times and mix well. Add 50 μL to each well and place on a 96-well plate shaker. Shake at 100 rpm for 15 min in the dark.

[0253] 2.3 Instrumental Detection: Turn on the multi-mode microplate reader and computer software. Place the shaken 96-well plate into the multi-mode microplate reader and detect the luciferase fluorescence intensity. Remove the 96-well plate and turn off the instrument and computer.

[0254] 3. Calculation of cell killing activity

[0255] After obtaining the luc values ​​of all wells, calculate the cytotoxic activity using the following formula.

[0256] Cell-killing activity = (average luc value of target cells alone - luc value of co-culture wells) / average luc value of target cells alone × 100%

[0257] (8) Multi-round stimulation

[0258] Target cells and effector cells were counted, and the cell viability was over 85%.

[0259] In multiple rounds, the effector-to-target ratio of effector cells to target cells was 3:1. Effector cells and target cells were co-incubated in 24-well plates.

[0260] Every 48 hours, the cells were homogenized, counted using a cell counter, and analyzed by flow cytometry to calculate target cell residue and effector cell expansion.

[0261] Based on the effector-to-target ratio of effector cells and target cells in multiple rounds of stimulation, corresponding target cells are added in each round; and the detection continues after 48 hours.

[0262] II. Test Results

[0263] 1. Expression of CARγδT cells prepared by lentiviral infection

[0264] Figure 3 shows the positive rates and MFI (mean fluorescence intensity) of CARγδT cells (CLL1-LV) prepared by lentiviral infection after 15 days of activation and CARγδT cells (CLL1-TRAC) prepared by site-directed integration at the TRAC site. Figure 3 shows that, compared with lentivirus, the non-viral site-directed integration method can achieve efficient transduction and expression of the CAR gene and improve the MFI intensity.

[0265] 2. Cell expansion curve

[0266] Figure 4 shows the expansion curves of CARγδT cells (CLL1-LV) prepared by lentiviral infection and CARγδT cells (CLL1-TRAC) prepared by site-directed integration at the TRAC site. Figure 4 shows that a non-viral site-directed integration method can achieve efficient expansion of CARγδT cells.

[0267] 3. Cell viability during cell culture

[0268] Figure 5 shows the viability of CARγδT cells (CLL1-LV) prepared by lentiviral infection and CARγδT cells (CLL1-TRAC) prepared by site-directed integration at the TRAC site. Figure 5 indicates that the non-viral site-directed integration method does not affect the viability of CARγδT cells during the culture phase.

[0269] 4. γδ2+ expression ratio of CARγδT cells prepared by lentiviral infection and site-specific integration with TRAC sites

[0270] Figure 6 shows the γδ2+ expression ratio of CARγδT cells (CLL1-LV) prepared by lentiviral infection and CARγδT cells (CLL1-TRAC) prepared by site-directed integration at the TRAC site. Figure 6 indicates that a higher proportion of γδ2+ can be achieved using a non-viral site-directed integration method.

[0271] 5. Memory cell ratio

[0272] Figure 7 shows the ratio of memory cells between CARγδT cells (CLL1-LV) prepared by lentiviral infection and CARγδT cells (CLL1-TRAC) prepared by site-directed integration with the TRAC site. Figure 7 indicates that using a non-viral site-directed integration method can increase the proportion of CD62L+CD45RA- cells.

[0273] 7. Comparison of short-term lethality

[0274] Figure 8 shows the killing effect of CARγδT cells (CLL1-LV) prepared by lentiviral infection and CARγδT cells prepared by TRAC site-directed integration on AML tumor cell lines. Figure 8 shows that CARγδT cells prepared by non-viral site-directed integration can achieve highly efficient killing of HL60 (human promyelocytic leukemia cells) and THP1 (human monocytic leukemia cells).

[0275] 8. Comparison of amplification capabilities under multiple rounds of stimulation

[0276] Figure 9 shows a comparison of the multi-round stimulation amplification capacity of CARγδT cells (CLL1-LV) prepared by lentiviral infection and CARγδT cells (CLL1-LV) prepared by TRAC site-directed integration. Figure 9 indicates that, in multiple rounds of stimulation, CARγδT cells prepared by TRAC site-directed integration exhibit superior amplification compared to CARγδT cells prepared by lentiviral infection, while simultaneously achieving sustained killing of THP1.

[0277] Example 3: Comparison of the activity of CLL CARγδT cells integrated at different sites

[0278] In this embodiment, the activity detection method of Example 2 was used to detect the activity of CLL CARγδT cells (CLL1-REG-γδT cells, CLL1-CISH-γδT cells, CLL1-PD-1-γδT cells, and CLL1-TRAC-γδT cells) at different insertion sites. The detection results are as follows.

[0279] 1. Cell expression status on day 11 after electroporation

[0280] Figure 10 shows the CAR expression of CLL1 CARγδT cells integrated at different sites. Figure 10 shows that, on day 11 after electroporation, the CLL1 CAR structure can be efficiently integrated at multiple sites using this technique, with a positive rate of 40%-65% at harvest, which is relatively high. The CAR MFI integrated at the TRAC site is the strongest.

[0281] 2. Cell growth curve

[0282] Figure 11 shows the amplification curves of CLL CARγδT cells integrated at different sites during the culture phase. Figure 11 indicates that, based on the amplification curves, the amplification fold of CARγδT cells prepared by site-directed integration is slightly lower than that of unedited γδT cells. Among them, CARγδT cells integrated at the TRAC site amplified the most, while the amplification fold of CARγδT cells integrated at the PD-1 site, regnase-1 site, and CISH site showed no significant difference.

[0283] 3. Cell viability during cell culture

[0284] Figure 12 shows the viability of CLL CARγδT cells integrated at different sites during the culture phase. Figure 12 indicates that, based on the viability line graph, the viability of CARγδT gene-edited cells prepared through site-specific integration was low on Day 3, but recovered to over 90% on Day 5.

[0285] The operation of targeted integration can have a significant impact on cell viability. By optimizing the viability recovery system after electroporation, cell viability can be restored and maintained at over 90% after Day 5.

[0286] 4. CD3+ expression ratio in each group of cells

[0287] Figure 13 shows the expression ratios of CD3 and γδ2 in CLL CAR γδT cells integrated at different sites during the culture phase. Figure 13 indicates that CAR integration into multiple gene sites has no significant effect on the CD3+ ratio and γδ2+.

[0288] 5. Proportion of CCR7+ memory cells at harvest

[0289] Figure 14 shows the proportion of CCR7+ memory cells in CLL CARγδT cells integrated at different sites at harvest. Figure 14 indicates that CAR integration into the negative regulatory site can increase the proportion of CCR7+ memory cells, and integration into the CISH site results in the highest proportion of CCR7+CD45RA+ cells; it also indicates that CAR integration into the negative regulatory site can increase the proportion of CD62L+ memory cells, and integration into the CISH site results in the highest proportion of CD62L+CD45RA+ cells.

[0290] 6. Comparison of short-term killing ability of CARγδT cells integrated at different sites

[0291] Figure 15 shows a comparison of the short-term killing ability of CAR-γδTs integrated at different sites. Figure 15 shows that CAR-γδTs prepared by site-directed integration all maintained strong killing activity against HL60 cells. More specifically, CLL1-REG>CLL1-CISH≈CLL1-PD-1>CLL1-TRAC>γδT; indicating that CAR-γδTs prepared by site-directed integration all maintained strong killing activity against THP1 cells: CLL1-REG>CLL1-CISH≈CLL1-PD-1>≈CLL1-TRAC>γδT.

[0292] 7. Comparison of multiple rounds of stimulation of CARγδT cells integrated at different sites

[0293] Figure 16 shows the expansion and killing of effector cells in each group during multiple rounds of stimulation. Figure 16 indicates that CAR-γδT prepared by site-directed integration technology, due to the simultaneous knockout of negative regulatory genes and CAR knock-in, exhibited improved maintenance and expansion during multiple rounds of in vitro stimulation compared to natural γδT, with CLL1-REG showing the best expansion. Furthermore, CAR-γδT prepared by site-directed integration technology, due to the simultaneous knockout of negative regulatory genes and CAR knock-in, demonstrated enhanced sustained killing ability of target cells during multiple rounds of in vitro stimulation, with CLL1-REG exhibiting the strongest sustained killing ability.

[0294] Example 4: Preparation of SuperγδT cells

[0295] 1. Design and preparation of dsDNA: dsDNA is a double-stranded DNA with closed ends, prepared by GenScript.

[0296] The amino acid sequence of CD8a-NKG2D-3TM-z-GFP is as follows:

[0297] (The amino acid sequences of CD8 signal peptide, NKG2D extracellular sequence, CD3 hinge region sequence, CD3 transmembrane region sequence, CD3Z intracellular sequence, T2A, and GFP are listed in order (SEQ ID NO: 26))

[0298] The nucleotide sequence encoding NKG2D-3TM-z-GFP (containing the T2A peptide and GFP) is as follows:

[0299]

[0300] The amino acid sequence of the chimeric antigen receptor NKG2D-3TM-z is as follows:

[0301] The nucleotide sequence encoding the chimeric antigen receptor NKG2D-3TM-z is as follows:

[0302] The amino acid sequence of CD8α in the hinge region is as follows:

[0303] The amino acid sequence of the transmembrane region CD8α is as follows:

[0304] The amino acid sequence of the transmembrane region CD3z is as follows:

[0305] The amino acid sequence of the intracellular signal transduction region derived from CD3ζ is as follows:

[0306] The amino acid sequence of the co-stimulatory signal transduction region 4-1BB is as follows:

[0307] The amino acid sequence of the guide peptide CD8α is as follows:

[0308] The nucleotide sequence encoding the GFP peptide is as follows:

[0309] The nucleotide sequence encoding the T2A peptide is as follows:

[0310] dsDNA-5 corresponding to NKG2D-3TM-z targeting the TARC site was synthesized. The donor template included a left homologous arm sequence (SEQ ID NO: 15), a promoter sequence (SEQ ID NO: 11), a nucleotide sequence encoding NKG2D-3TM-z–GFP (containing T2A peptide and GFP) (SEQ ID NO: 27), a transcription terminator sequence (SEQ ID NO: 12), and a right homologous arm sequence (SEQ ID NO: 16) in the 5'-3' direction.

[0311] Guide RNA N20 sequence:

[0312] TRAC: 5'-AGAGTCTCTCAGCTGGTACACGG-3' (SEQ ID NO: 1)

[0313] 2. Cell culture:

[0314] The cell culture process is shown in Figure 17, including: sorting and activation; non-viral site-specific integration; amplification; and harvesting.

[0315] In brief:

[0316] On Day 4, PBMC cells were resuscitated and sorted with TCRα / β magnetic beads. Cells sorted with magnetic beads were activated with zoledronic acid to form γδT cells. Four days after activation (Day 0), a mixture containing gene editing tools and donor template was introduced into γδT cells via electroporation. One day after electroporation (Day 1), γδT complete culture medium was added and the cells were incubated. On Day 3 after electroporation (Day 3), dasatinib and vitamin C were added to the γδT complete culture medium. On Day 5, Day 7, and Day 9 during the culture process, the proportion of CD3, Vδ2+, and CAR positivity were detected by flow cytometry. CAR-T cells were harvested on Day 11 after electroporation (Day 11) for cell killing experiments. The remaining cells were cryopreserved using a programmed freezing system.

[0317] 2.1 Cell sorting activation

[0318] 1. Cell sorting: Take the frozen or freshly isolated PBMCs out of the liquid nitrogen tank, quickly transfer them through the transfer window to the cell chamber, and immediately place them in a 37°C water bath to thaw;

[0319] 2. Take a 50ml centrifuge tube, gently mix the melted cell suspension, mix the cells, and take a sample for counting;

[0320] 3. Collect cells, sample for flow cytometry analysis, centrifuge at 300g for 10 minutes, and remove the supernatant;

[0321] 4. Resuspend cells in Miltenyi sorting buffer (EDTA / DPBS + 1% HSA (human serum albumin)), resuspend cells according to the reference dosage of CD4 magnetic beads and CD8 magnetic beads, or αβT sorting kit, and add sorting magnetic beads;

[0322] 5. After mixing, incubate in a refrigerator at 2-8℃ for 15 minutes;

[0323] 6. Resuspend the cells in buffer, centrifuge at 300g for 10 minutes, and discard the supernatant;

[0324] 7. Follow the 0.5mL buffer / 10 8 Resuspend the cells in sorting solution; (add 500 μL if less than 500 μL);

[0325] 8. Separate negative and positive cells using LS columns and magnetic racks;

[0326] 9. Centrifuge at 300g for 8 minutes and discard the supernatant;

[0327] 10. Count the isolated negative and positive cells separately, according to (2-3) × 10⁻⁶. 6 Cells were resuspended at a density of 1 / ml by adding an appropriate amount of γδT complete medium (containing 5 μM M3814, 10% FBS or 10% HPL) and cultured in a CO2 incubator; 5-10 μM beryllium phosphate was added to the γδT cell medium for activation.

[0328] 2.2 Cell electroporation:

[0329] Three to four days after cell activation, the cells were pipetted and counted. An electroporation mixture was prepared according to the LONZA electroporation system, at a concentration of (0.8–1) × 10⁶ cells / cell. 6 The electroporation system corresponding to each cell is as follows:

[0330] Depending on the insertion site, different sgRNAs and different dsDNAs are selected. For example, if the insertion site is a TRAC site, then the sgRNA is 5'-AGAGTCTCTCAGCTGGTACACGG-3' (SEQ ID NO: 1) and the dsDNA is 5'-.

[0331] After preparation, incubate at room temperature for 15 minutes;

[0332] According to the required cell quantity for each group in the RNP preparation table, add (0.8–1) × 10⁻⁶ cells to each group. 6 One cell (resuspended in 10 μL with P3 buffer);

[0333] Transfer to the electroplating strips, avoiding the formation of air bubbles, and complete the electroplating using the LONZA EH100 electroplating instrument program.

[0334] Prepare a complete γδT medium containing 1–5 μM M3814, 10% FBS or 10% HPL, add 100 μL to each well, and incubate at 37°C for 15 min.

[0335] After incubation, transfer to a 96-well plate and add γδT complete medium containing 5 μM M3814, 10% FBS or 10% HPL to each well.

[0336] 2.3 Cell Culture:

[0337] (1) 24 hours after electroporation, fresh culture medium was added and the cells were transferred to 48-well or 24-well plates according to the cell density;

[0338] (2) On Day 3 after electroporation, 10-30 nM Dasatinib and 10-50 μM Vitamin C were added to the culture medium. The cells were passaged according to the cell density to maintain the cell density at 0.5 E6 to 3 E6 / mL.

[0339] (3) During the culture process (such as Day 5, Day 7 and Day 9 after electroporation), the cell density, viability, positivity rate and purity were detected (e.g. CD3 ratio, Vδ2+ ratio and CAR positivity rate).

[0340] 2.4 Cell harvesting: Cells were harvested on Day 11 after electroporation to obtain SuperγδT cells, which are CAR genes (SEQ ID NO: 24) with the nucleotide sequence of the NKG2D gene knocked into the TRAC site of the γδT cell genome.

[0341] Example 5: Activity assay of SuperγδT cells prepared in Example 4

[0342] I. Activity detection:

[0343] (1) Phenotypic detection:

[0344] During cell culture, a certain amount of cells are taken for testing, and antibodies include anti-NKG2D, anti-γδ2, and anti-CD3.

[0345] After incubation with flow cytometry antibody, the cells were washed with FACS buffer (PBS + 0.25% BSA) and the expression of cell surface markers was detected by flow cytometry.

[0346] (2) Experimental methods for determining cell viability during the cell culture stage

[0347] 1. Preparation of cell suspension: The cell culture to be tested (e.g., UTD cells (T cells not transduced with CAR) and SuperγδT cells prepared in Example 4) was pipetted to prepare a single-cell suspension, and the cell concentration was adjusted to 1-3 M / mL (i.e., (1-3) × 10⁻⁶). 6 (cells / mL).

[0348] 2. Staining: Take 20 μL of cell suspension, add 20 μL of AOPI staining solution (commercially available), mix gently, and add 20 μL to a cell counting chamber.

[0349] Detection: Insert the cell counting chamber into the CountStar counter to detect cell viability.

[0350] (3) Experimental method for determining cell expansion curves

[0351] 1. Preparation of cell suspension: The cell culture to be tested (e.g., UTD cells (T cells not transduced with CAR) and SuperγδT cells prepared in Example 4) was pipetted to prepare a single-cell suspension, and the cell concentration was adjusted to 1-3 M / mL.

[0352] 2. Staining: Take 20 μL of cell suspension, add 20 μL of AOPI staining solution (commercially available), mix gently, and add 20 μL to a cell counting chamber.

[0353] Detection: Insert the cell counting chamber into the CountStar counter to detect cell density. Cell count = cell density × cell culture volume.

[0354] (4) Experimental method for determining the γδ2+ expression ratio in CARγδT cells

[0355] 1. Cell preparation

[0356] Take an appropriate amount of cell suspension (e.g., UTD-γδT cells (γδT cells not transduced with CAR) and SuperγδT cells prepared in Example 4), wash the cells 2-3 times with PBS, resuspend the cells in PBS containing 0.25% BSA (bovine serum albumin), and adjust the cell concentration to a suitable range, usually 1×10⁻⁶. 6 -1×10 7 Cells / mL.

[0357] 2. Staining

[0358] Add 1 μL of γδ2TCR antibody to each sample, incubate at 4°C in the dark for half an hour, and then wash the cells 2-3 times with PBS containing 0.25% BSA to remove unbound antibodies.

[0359] 3. Flow cytometry detection

[0360] The prepared cell suspension was analyzed by flow cytometry to detect the γδ2+ expression ratio of CARγδT cells.

[0361] (5) External killing (short-term):

[0362] 1. Target cell plate

[0363] 1.1 Target cell preparation:

[0364] 1.1.1 The target cells are in good logarithmic growth phase with a cell viability of over 85%.

[0365] 1.1.2 Count the target cells according to standard cell counting procedures, and take 2 × 10⁻⁶ cells. 6Transfer the target cells to a 15ml centrifuge tube, centrifuge at 300g for 8 minutes, remove the supernatant, and resuspend the target cells in T0 medium until the cell density is 2×10⁶ cells / mL. 5 per ml.

[0366] 1.1.3 Carefully transfer the diluted target cells into the sample loading well, and use a pipette to add the target cells into a black, transparent, flat-bottomed 96-well plate at a rate of 50 μL / well.

[0367] 1.2 Effector cell plate

[0368] 1.2.1 Effector cell preparation: The cell dosage was calculated according to effector-to-target ratios of 1:3, 3:1, and 1:1, respectively, and was 1 / 9 × 10⁻⁶ cells. 4 1, 3×10 4 1×10 4 Count the effector cells, take the required number of SuperγδT cell samples into a 15ml centrifuge tube, centrifuge at 300g for 8min, and discard the supernatant.

[0369] 1.2.2 γδT cells were resuspended in T0 medium (X-vivo + 5% FBS), and the effector cell density was adjusted according to the effector-to-target ratio. Three effector-to-target ratios were set: 1:3, 3:1, and 1:1.

[0370] 1.2.3 Add effector cells to the well plates at effector-to-target ratios of 1:3, 3:1, and 1:1, 50 μL / well.

[0371] 1.3 Setting up the target cell control group

[0372] Add 50 μL of target cells and 50 μL of T0 medium (X-vivo + 5% FBS) to the wells of the target cell control group to make the total culture volume of the target cell control group consistent with the total culture volume of the co-culture experimental group.

[0373] 2. Detect luc value

[0374] 2.1 Cell co-culture: Place the 96-well plate with the added samples in a CO2 incubator and co-culture for 18-24 hours.

[0375] 2.2 Adding the detection reagent: Melt steadyglo luciferase (commercially available) at room temperature in the dark. Dilute the steadyglo required for the experiment with PBS 3 times and mix well. Add 50 μL to each well and place on a 96-well plate shaker. Shake at 100 rpm for 15 min.

[0376] 2.3 Instrumental Detection: Turn on the multi-mode microplate reader and computer software. Place the shaken 96-well plate into the multi-mode microplate reader and detect the luciferase fluorescence intensity. Remove the 96-well plate and turn off the instrument and computer.

[0377] 3. Calculation of cell killing activity

[0378] After obtaining the luc values ​​of all wells, calculate the cytotoxic activity using the following formula.

[0379] Cell-killing activity = (average luc value of target cells alone - luc value of co-culture wells) / average luc value of target cells alone × 100%

[0380] II. Test Results

[0381] 1. Viability of SuperγδT cells during the culture phase

[0382] The viability of SuperγδT cells during the culture phase is shown in Figure 18. Figure 18 shows that on the fifth day after electroporation, the viability of SuperγδT cells gradually recovered and maintained a high viability of over 95%.

[0383] 2. Cell expansion fold during culture phase

[0384] Figure 19 shows the expansion of SuperγδT cells during the culture phase. Figure 19 indicates that during the culture phase, the expansion fold of SuperγδT cells was not significantly different from that of UTD (untransduced CAR T cells).

[0385] 3. Purity of γδ2 in SuperγδT cells during culture

[0386] Figure 20 shows the γδ2 purity of SuperγδT cells during the culture phase. Figure 20 indicates that SuperγδT cells prepared using the site-directed integration method maintained high γδ2 purity.

[0387] 4. Positive rate of SuperγδT cells at harvest

[0388] The positivity rate of SuperγδT cells at harvest is shown in Figure 21. Figure 21 shows that the positivity rate of SuperγδT cells prepared using the site-directed integration method can reach 85%.

[0389] 5. Short-term killing effect of SuperγδT cells on AML tumor cell lines

[0390] Figure 22 shows the short-term killing effect of SuperγδT cells on AML tumor cell lines. Figure 22 indicates that SuperγδT cells prepared using the site-directed integration method can achieve highly efficient killing of HL60 cells in a short time; SuperγδT cells prepared using the site-directed integration method can also achieve strong killing of THP1 cells in a short time.

[0391] While the above descriptions are merely examples of specific embodiments of the present invention, those skilled in the art should understand that these are only illustrative, and the scope of protection of the present invention is defined by the appended claims. Those skilled in the art can make various changes or modifications to these embodiments without departing from the principles and essence of the present invention, and all such changes or modifications shall fall within the scope of protection of the present invention.

Claims

1. A method for preparing CAR-T cells, comprising the following steps: Introducing gene-editing tools into T cells to knock out genes at specific sites in the T cell genome; and A donor template is introduced into T cells to knock the CAR gene into the specific site.

2. The method according to claim 1, wherein the gene at the specific site includes the TRAC gene, PD1 gene, CISH gene, and Regnase-1 gene.

3. The method according to claim 1 or 2, wherein the specific site comprises: TRAC site, PD1 site, CISH site, and Regnase-1 site.

4. The method according to any one of claims 1-3, wherein, The gene editing tool is selected from the CRISPR / Cas system; Optionally, the CRISPR / Cas system includes the Cas protein and sgRNA.

5. The method according to claim 4, wherein the Cas protein comprises any one of the following: spCas9, AsCas12a, or LbCas12a; The sgRNA includes any one of the following sites: TRAC site, PD1 site, CISH site, and Regnase-1 site; Optionally, the sgRNA sequence targeting the TRAC site is: TRAC: 5'-AGAGTCTCTCAGCTGGTACACGG-3' (SEQ ID NO: 1); The sgRNA sequence targeting the PD1 site is as follows: PD1: 5'-CGACTGGCCAGGGCGCCTGT-3' (SEQ ID NO: 2); The sgRNA sequence targeting the CISH site is as follows: CISH: 5'-GGCGCATCCTCCTTAGGCAT-3' (SEQ ID NO: 3); The sgRNA sequence targeting the Regnase-1 site is as follows: Regnase-1: 5'-AAGGAGGTCTTCTCCTGCCG-3' (SEQ ID NO: 4).

6. The method according to any one of claims 1-5, wherein the donor template is plasmid DNA, dsDNA or ssDNA; Optionally, the donor template is dsDNA; Alternatively, the donor template includes a left homologous arm sequence, a promoter sequence, a CAR gene, a transcription terminator sequence, and a right homologous arm sequence in the 5'-3' direction; Further optionally, the donor template includes a left homologous arm sequence, a promoter sequence, a CAR gene, a nucleotide sequence encoding a T2A peptide, a marker gene sequence, a transcription terminator sequence, and a right homologous arm sequence in the 5'-3' direction.

7. The method of claim 6, wherein the gene editing tool and the donor template are introduced into T cells in the form of a mixture via electroporation transfection; Optionally, the Cas protein, sgRNA, and dsDNA are introduced into T cells in a mixture via electroporation transfection.

8. The method of claim 6, wherein the CAR gene comprises a nucleotide sequence encoding an extracellular antigen recognition domain, a nucleotide sequence encoding a hinge region, a nucleotide sequence encoding a transmembrane region, and a nucleotide sequence encoding an intracellular domain; Optionally, the donor template further comprises a nucleotide sequence encoding a signal peptide, and the nucleotide sequence encoding the signal peptide is located between the promoter sequence and the nucleotide sequence encoding an extracellular antigen recognition domain; Alternatively, the signal peptide is derived from CD8α; Further optionally, the amino acid sequence of the signal peptide is shown in SEQ ID NO:

5.

9. The method according to claim 8, wherein the extracellular antigen recognition domain targets one, two, or more of the following ligands: CD19, CD20, CD22, CD30, CD33, CD123, BCMA, SLAMF7, CD5, CD7, CLL1, NKG2D, DNAM1, NKp30, NKp44, NKp46, EGFR, EGFRv III, CEA, MUC1, MUC16, EphA2, IL13Rα2, CD70, CD171, PSMA, PSCA, ROR1, VEGFR2, cMet, FAP, GPC3, Claudin18.2, CD138, NKG2D, CD38, CD44v6, Lewis Y, mesothelin, HER2, GD2, L1-CAM, FR, and CAIX; optionally, the extracellular antigen recognition domain targets CLL1 or NKG2D ligands.

10. The method of claim 8, wherein the hinge region is derived from one or more of IgG1, IgG4, CD4, CD7, CD28, CD84, and CD8α; optionally, the hinge region is derived from CD8α; more preferably, the amino acid sequence of the hinge region is as shown in SEQ ID NO: 6; and / or The transmembrane region is derived from one or more of CD3z, CD4, CD7, CD8α, CD28, CD80, CD86, CD88, 4-1BB, CD152, OX40, and Fc70; optionally, the transmembrane region is derived from CD8α or CD3z; more preferably, the amino acid sequence of the transmembrane region is as shown in SEQ ID NO: 7 or SEQ ID NO:

8.

11. The method of claim 8, wherein the intracellular domain comprises an intracellular signal transduction region; optionally, it further comprises a co-stimulatory signal transduction region.

12. The method according to claim 11, wherein the intracellular signal transduction region is derived from one or more of CD3ζ, CD3γ, CD3δ, CD3ε, CCD5, CD22, CD79a, CD79b, FcRγ, FcRβ, CD66d, DAP10, DAP12, and Syk; optionally, the intracellular signal transduction region is derived from CD3ζ; more preferably, the amino acid sequence of the intracellular signal transduction region is as shown in SEQ ID NO: 9; and / or The co-stimulatory signal transduction region is derived from one, two, or more of CD2, CD3, CD7, CD27, CD28, CD30, CD40, CD83, CD244, 4-1BB, OX40, LFA-1, ICOS, LIGHT, NKG2C, NKG2D, DAP10, B7-H3, and MyD88; optionally, the co-stimulatory signal transduction region is derived from 4-1BB; more preferably, the amino acid sequence of the co-stimulatory signal transduction region is as shown in SEQ ID NO:

10.

13. The method according to claim 6, wherein the promoter is selected from the SFFV promoter, the CMV promoter, or the EF1α promoter; optionally, the nucleotide sequence of the EF1α promoter is shown in SEQ ID NO: 11; The nucleotide sequence of the transcription terminator sequence is shown in SEQ ID NO:

12.

14. The method of claim 6, wherein the nucleotide sequence encoding the T2A peptide is as shown in SEQ ID NO: 13; and / or The marker gene sequence is an EGFP fluorescent protein gene or a GFP fluorescent protein gene; optionally, the nucleotide sequence of the GFP fluorescent protein gene is shown in SEQ ID NO:

14.

15. The method according to any one of claims 6-14, wherein the left homologous arm sequence and the right homologous arm sequence for the TRAC site in the donor template are as shown in SEQ ID NO: 15 and SEQ ID NO: 16, respectively; or The left and right homologous arm sequences for the PD1 site in the donor template are shown in SEQ ID NO: 17 and SEQ ID NO: 18, respectively; or The left and right homologous arm sequences for the CISH site in the donor template are shown in SEQ ID NO: 19 and SEQ ID NO: 20, respectively; or The left and right homologous arm sequences for the Regnase-1 site in the donor template are shown in SEQ ID NO: 21 and SEQ ID NO: 22, respectively.

16. The method according to any one of claims 1-15, wherein the T cell is a γδT cell.

17. The method according to any one of claims 1-16, comprising the following steps: (1) Preparation of T cells PBMC cells were revived, and TCRα / β magnetic beads were added for sorting. Cells sorted by magnetic beads were then activated with zoledronic acid. (2) Introducing gene editing tools and donor templates into T cells Three to four days after activation, a mixture containing gene editing tools and donor templates was introduced into T cells via electroporation. One day after electroporation, γδT complete medium was added and the cells were incubated. On the third day after electroporation, dasatinib and vitamin C were added to the γδT complete medium. CAR-T cells were harvested on the eleventh day after electroporation.

18. The method according to claim 17, wherein the concentration of zoledronic acid is 5-10 μM; The complete γδT culture medium contains 1-5 μM M3814 inhibitor and 10% fetal bovine serum or 10% human platelet lysate; The concentration of dasatinib is 10-30 nM; The concentration of vitamin C is 10-50 μM.

19. A type of CAR-T cell, which is one of the following types of cells: (1) CLL1-REG-γδT cells, which are CAR genes containing nucleotide sequences encoding CLL1 antibodies knocked into the Regnase-1 site of the genome of γδT cells; (2) CLL1-CISH-γδT cells, which are CAR genes containing nucleotide sequences encoding CLL1 antibodies knocked into the CISH site of the γδT cell genome. (3) CLL1-PD-1-γδT cells, which are CAR genes containing nucleotide sequences encoding CLL1 antibodies knocked into the PD1 site of the γδT cell genome; (4) CLL1-TRAC-γδT cells, which are CAR genes containing nucleotide sequences encoding CLL1 antibodies knocked into the TRAC site of the genome of γδT cells. (5) SuperγδT cells, which are CAR genes containing the NKG2D gene sequence knocked into the Regnase-1, CISH, PD1 or TRAC sites of the γδT cell genome.

20. The CAR-T cell according to claim 19, wherein the CAR gene is shown in SEQ ID NO: 23 or SEQ ID NO:

24.

21. The CAR-T cells according to claim 19 or 20, which are prepared by any one of claims 1-18.

22. Use of CAR-T cells according to any one of claims 19-21 in the preparation of antitumor drugs; Optionally, the drug is used to treat acute T-lymphoblastic leukemia (T-ALL), non-small cell lung cancer (NSCLC), acute myeloid leukemia (AML), hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and acute promyelocytic leukemia.